PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
Puma Biotechnology
Puma Biotechnology, Inc. 2020 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology
Video Puma Biotechnology Soars on Breast Cancer Drug Results - ABC News
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
$51.61 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Opera News
Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results, Beats Estimates By $0.11 EPS - Opera News
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Here's Why Puma Biotechnology Tumbled Today | The Motley Fool
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
Puma Biotechnology - Crunchbase Company Profile & Funding
PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology
